Divi's Laboratories (NSE:DIVISLAB) Other Current Liabilities: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:DIVISLAB Divi's Laboratories Ltd NSE:DIVISLAB
87 GF Score
Price ₹9,100.00
GF Value ₹6,982.17
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Divi's Laboratories Other Current Liabilities?

Divi's Laboratories NSE:DIVISLAB -1.62% 87 Other Current Liabilities is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:DIVISLAB with a GF Score™ of 87/100 and a GF Value™ of ₹6,982.17 (Modestly Overvalued). The stock has 8 warning signs investors should review.

Divi's Laboratories's other current liabilities for the quarter that ended in Jun. 2026 was ₹0 Mil.

Divi's Laboratories's quarterly other current liabilities increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹3,430 Mil) but then declined from Mar. 2026 (₹3,430 Mil) to Jun. 2026 (₹0 Mil).

Divi's Laboratories's annual other current liabilities increased from Mar. 2024 (₹730 Mil) to Mar. 2025 (₹1,140 Mil) and increased from Mar. 2025 (₹1,140 Mil) to Mar. 2026 (₹3,430 Mil).

Divi's Laboratories Other Current Liabilities Related Terms

Divi's Laboratories Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Divi's Laboratories's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Divi's Laboratories Other Current Liabilities Chart

Divi's Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 279.30 550.00 730.00 1,140.00 3,430.00

Divi's Laboratories Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 5,530.00 0.00 3,430.00 0.00
NSE:DIVISLAB
87GF Score
Divi's Laboratories Ltd NSE:DIVISLAB
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Divi's Laboratories Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of ₹0 Mil mean?
Divi's Laboratories (NSE:DIVISLAB) has a Other Current Liabilities of ₹0 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Divi's Laboratories.
Is Divi's Laboratories' Other Current Liabilities too high?
Divi's Laboratories' current Other Current Liabilities is ₹0 Mil. Overall, Divi's Laboratories has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Divi's Laboratories' Other Current Liabilities compare to ZTS?
Divi's Laboratories' Other Current Liabilities of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Divi's Laboratories. Divi's Laboratories's current Other Current Liabilities is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Divi's Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Divi's Laboratories (NSE:DIVISLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹6,982.17, compared to a current price of ₹9,100.00 — trading 30.3% above its estimated fair value. The current Other Current Liabilities is ₹0 Mil. Divi's Laboratories' overall GF Score™ is 87/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Divi's Laboratories (NSE:DIVISLAB), the current Other Current Liabilities is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Divi's Laboratories (NSE:DIVISLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Divi's Laboratories stock appears to be overvalued. The current stock price of ₹9,100.00 is trading 30.3% above its estimated GF Value™ of ₹6,982.17. GuruFocus considers Divi's Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:DIVISLAB:

  • Other Current Liabilities: ₹0 Mil
  • GF Value™: ₹6,982.17 vs. price of ₹9,100.00 (30.3% above fair value)
  • GF Score™: 87/100 with 8 warning signs

No single metric tells the full story. See the NSE:DIVISLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Divi's Laboratories Business Description

Other Exchanges 532488:India
Address Cyber Hills, Divi Towers, 1-72/23(P)/DIVIS/303, Gachibowli, Hyderabad, TG, IND, 500032
Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. It is engaged in the manufacture of Active Pharmaceutical ingredients (API), Intermediates, and Nutraceutical ingredients, with a predominance in exports. It also, through its custom synthesis, supports pharma companies for their patented products business from gram-scale requirements for clinical trials to launch, as well as late-life cycle management. Geographically, the company derives maximum revenue from Europe, and the rest from America, India, Asia (excluding India), and the Rest of the world.
87GF Score

Get the complete analysis for NSE:DIVISLAB

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹9,100.00
Price
₹6,982.17
GF Value